Stevanato Group (NYSE:STVN) Updates FY 2024 Earnings Guidance

Stevanato Group (NYSE:STVN) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.517-0.539 for the period, compared to the consensus earnings per share estimate of 0.490. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.

Stevanato Group Stock Down 1.1 %

Shares of NYSE:STVN opened at €19.38 ($21.07) on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.74 and a quick ratio of 1.13. The business’s 50-day moving average is €19.57 and its 200-day moving average is €20.33. Stevanato Group has a 1 year low of €16.56 ($18.00) and a 1 year high of €34.73 ($37.75).

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The business had revenue of €259.60 million during the quarter, compared to analyst estimates of €254.92 million. Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.15 earnings per share. On average, research analysts anticipate that Stevanato Group will post 0.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on STVN. Morgan Stanley dropped their price target on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Citigroup dropped their price target on Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.